MOTS-c is not FDA-approved and long-term human safety data does not exist
In a real-world cohort, six-month semaglutide loss was about 8.8%, roughly 0.6 to 0.8 of the STEP figure, mostly through adherence and persistence rather than a weaker drug. Read the trial number as a ceiling to translate down toward your own body and your own consistency, not as a forecast
These innovations are geared toward enhancing bioavailability, minimizing gastrointestinal side effects, and broadening therapeutic applications beyond diabetes and obesity to include cardiovascular and neurodegenerative conditions
There should never be an incentive to prescribe for any patient
[115] This functionality is lost in vitamin B 12 deficiency, resulting in an increased homocysteine level and the trapping of folate as 5-methyl-tetrahydrofolate, from which THF (the active form of folate) cannot be recovered